Close Menu

cancer of unknown primary

Spun out of Moffitt Cancer Center, M2Gen and the Total Cancer Care protocols promise rapid advancements in precision medicine, starting with oncology.

The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.

Investigators studied 442 patients with CUP and found mutations that could inform a specific treatment decision in more than half of them.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

American Society of Clinical Oncology presentations show the unmet need for methods to predict autoimmune toxicities in checkpoint blockade-treated individuals.

The registry collects data on cancer genetics and aims to provide patients with access to quality NGS testing, among other things.

The study will use OncoDNA's liquid biopsy tech to profile and identify treatment options for 100 patients in Lebanon, Jordan, Saudi Arabia, and the UAE.

Giant platelets on a blood smear

The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.

Researchers found that telomeres were shorter in tumors than in normal tissues and longer in sarcomas and gliomas than in other cancers.

The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.